Abstract
Background There is no existing research on hormone overdose and misuse (HODM) in Chinese transgender and gender non-conforming (TGNC) population, and little is known in this field.
Objectives We aim to determine the definition and criteria of HODM in Chinese TGNCs, address the rate of HODM in Chinese TGNC population, explore related factors and behavioral risks, identify the probable causes, and explore long-term effects.
Methods We propose: (1) a mixed-method study comprising expert panel meetings and stakeholder engagement to identify HODM criteria, types and grades; (2) a cross-sectional study to quantify HODM prevalence, related factors and behavioral risks; (3) semi-structured interviews and focus groups to explore HODM motivations and reasons; and (4) a prospective cohort study to evaluate HODM long-term effects.
Ethics The study protocol was approved by the Medical Ethics Committee of Xiamen University (XDYX202210K27).
Dissemination Results will be published in international peer-reviewed journals, and a public-oriented version of the main findings will be prepared and disseminated through social media and online communities. The study will be completed before September 2023 except for the cohort study. Preliminary findings of the cohort study will be reported by March 2026.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethics Committee of Xiamen University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
zengbentuoxmu{at}outlook.com (B.-T.Z.); 32220192204453{at}stu.xmu.edu.cn (L.-P.L.); mtfwpf{at}gmail.com (P.-F.W.)
phq19991011{at}126.com (H.-Q.P.)
ltm21{at}mails.tsinghua.edu.cn (T.-M.L.)
yezhenyu1999{at}gmail.com (Z.-Y.Y.)
The hormones used are specified in Eligibility Criteria section. The follow-up timepoints are specified. Also, some typos are corrected.
Data Availability
This is a protocol and does not produce any data.
